Why pharma companies should file patents later in the R&D process
Life sciences innovators should take a different approach to prosecution, argues Mintz's Alex Trimble
Life sciences innovators should take a different approach to prosecution, argues Mintz's Alex Trimble
J&J subsidiary makes innovative use of IP acquired in $6.5 billion Momenta acquisition
Disputes over vaccine technology will continue to occupy headlines in 2023
03 January 2023
IAM looks back at some key stories from Brazil and Colombia over the last 12 months
29 December 2022
IAM looks back at the most important pharmaceuticals developments of the past 12 months
28 December 2022
Unleashing American Innovators in, Pride in Patent Ownership out of bill which is expected to hit Biden’s desk on Friday
20 December 2022
Companies who scored the most from US juries during the past 12 months include VLSI Technology, Complete Genomics Inc, Ravgen Inc, USAA and Columbia University
19 December 2022
Yielding patent protection rights won’t make products magically appear, says IPO Treasurer Dan Enebo
16 December 2022
Controversial Pride in Patent Ownership bill unlikely, other bills passed or possible
16 December 2022
The year’s largest acquisition sees several IP-backed rare disease treatments change hands
15 December 2022
Pharmaceutical patent holders have the unenviable task of providing evidence before IP courts to prove infringement to obtain a preliminary injunction decision to prevent launch of the infringing product to the market. Unfortunately, disparities in Turkish courts’ approaches to requests for determination of evidence are making a challenging job even harder.
14 December 2022
Qualcomm executive and Invent Together director discuss initiatives at IP Dealmakers conference in New York
13 December 2022
Unlock unlimited access to all IAM content